Suven Life Sciences will present positive Phase-2a study results for Ropanicant (SUVN-911) and updates on its innovation pipeline at the Neuroscience 2024 conference in Chicago from October 5-9, 2024.
AI Assistant
Suven Life Sciences Ltd
2024
Announcement
Find Answers
Ask about any part of the document to get insights, explanations, or key details.